Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.

Willemin, Marie-Emilie; Zannikos, Peter; Mannens, Geert; de Zwart, Loeckie; Snoeys, Jan

Willemin, Marie-Emilie; Zannikos, Peter; Mannens, Geert; de Zwart, Loeckie; Snoeys, Jan.

Afiliação

Willemin ME; Drug Metabolism and Pharmacokinetics, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium. mwille15@its.jnj.com.
Zannikos P; Janssen Research & Development, LLC, New Jersey, USA.
Mannens G; Drug Metabolism and Pharmacokinetics, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.
de Zwart L; Drug Metabolism and Pharmacokinetics, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.
Snoeys J; Drug Metabolism and Pharmacokinetics, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.

Clin Pharmacokinet ; 61(8): 1115-1128, 2022 08.

Article em En | MEDLINE | ID: mdl-35579824

Assuntos

Citocromo P-450 CYP3A; Modelos Biológicos; Administração Intranasal; Simulação por Computador; Citocromo P-450 CYP3A/metabolismo; Interações Medicamentosas; Humanos; Ketamina; Preparações Farmacêuticas/metabolismo; Estudos Prospectivos; Ticlopidina

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citocromo P-450 CYP3A / Modelos Biológicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Pharmacokinet Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google